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Abstract 
In addition to their established roles in host defence, Toll-like Receptors (TLRs) have 
emerging roles in control of homeostasis, injury and wound repair. The dsRNA-sensing 
receptor, TLR3, has been particularly implicated in such processes in several different 
tissues including the skin, intestine and liver, as well as in the control of reparative 
mechanisms in the brain, heart and kidneys, following ischemia reperfusion injury. In 
this review, we provide an overview of TLR3 signalling and functions in inflammation, 
tissue damage and repair processes, as well as therapeutic opportunities that may arise 
in the future from knowledge of such pathways.  
Keywords: Toll-like receptor 3; wound repair; homeostasis; ischemia reperfusion 
injury; poly(IC); UV-damage  
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BBB = blood-brain barrier, Bcl2 = B-cell CLL/lymphoma 2, CNS = Central nervous 
system, CXCL = C-X-C motif ligand, EBI3 = Epstein-Barr virus induced gene 3, 
FADD = Fas-associated death domain, HBV = Hepatitis B virus, HSC = Hepatic 
stellate cell, HSV = Herpes simplex virus, I/R = Ischemia reperfusion, IAV = Influenza 
A virus, IEC = Intestinal epithelial cell, IFN = Interferon, IL = Interleukin, IRF = 
Interferon regulatory factor, MAL = MyD88 adaptor-like, MAPK = Mitogen-activated 
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inducing IFN, UV = Ultraviolet, WNV = West Nile virus 
 
 
  
1. Introduction 
Pattern recognition receptors (PRRs) are widely studied in innate immune cells for their 
roles in host defence. In this context, they are tasked with detecting and responding to 
conserved pathogen-associated molecular patterns (PAMPs), which are essential for 
microbial survival and/or pathogenicity [1]. It is now clear that PRRs function more 
broadly as danger-sensing systems, detecting both pathogen- and host-derived factors 
that accumulate when homeostasis is perturbed. Indeed, PRRs have emerged as critical 
regulators of homeostasis and developmental processes. Such roles may relate to PRR 
functions in non-immune cells such as epithelial cells, where they are also expressed 
[2]. 
Of the PRR families, the Toll-like receptors (TLRs) have been most widely studied. 
These transmembrane receptors, which localize to both the plasma membrane and to 
endolysosomal compartments, play key roles in development, homeostasis and injury 
repair. For example, TLR2, which detects bacterial lipopeptides, maintains homeostasis 
at mucosal surfaces by promoting barrier integrity in intestinal epithelial cells (IECs) 
[2]. Along with TLR4, which recognizes Gram-negative bacterial lipopolysaccharide, 
TLR2 has also been implicated as a regulator of cardiovascular functions, 
thermoregulation and energy metabolism in the autonomic nervous system [3]. Such 
studies provide examples of roles for innate immune danger-sensors in regulating 
normal physiological processes to maintain homeostasis. Indeed, the capacity of TLRs 
to regulate the expression of genes involved in inflammation and repair processes, often 
in a tissue-specific manner, appears to be critical for maintenance of normal 
physiological processes [2]. 
TLR3 is a dsRNA-sensing TLR, first characterized as a regulator of anti-viral 
responses. However, subsequent studies demonstrated that TLR3 can also detect host-
derived RNA, thus enabling it to regulate injury repair processes. In this review, we 
provide an overview of TLR3 biology in the context of host defence and inflammation. 
We particularly focus on TLR3 functions in wound healing and in homeostatic control 
in the skin, gastrointestinal tract and liver, as well as during ischemia reperfusion (I/R) 
injury in the brain, heart and kidney (Fig. 1). Given that TLR3 agonists and antagonists 
already exist, manipulation of this pathway to accelerate tissue repair processes may be 
feasible in some pathophysiological settings. 
2. TLR3 signal transduction and its role in host defence 
2.1. Overview of TLR signalling 
A total of thirteen TLRs have been identified in humans and mice; ten in humans 
(TLR1-10) and twelve in mice (TLR1-9, 11-13) [4]. Each TLR recognizes cognate 
PAMPs, resulting in activation of distinct but overlapping signalling pathways through 
the initial recruitment of specific combinations of Toll/Interleukin (IL)-1 Receptor 
(TIR) domain-containing adaptor proteins. Briefly, upon activation, all TLRs, except for 
TLR3, recruit the adaptor protein myeloid differentiation primary response gene 88 
(MyD88), which contains a C-terminal TIR domain and an N-terminal death domain 
[5]. In the case of TLR4 and TLR2, MyD88-adaptor-like (MAL; also known as TIR 
domain-containing adaptor protein, TIRAP) acts as a bridging adaptor between MyD88 
and these TLRs. Recently, TLR5 in IECs [6], and TLR7 and TLR9 in macrophages [7], 
have also been shown to associate with MAL, thus implicating this adaptor in tissue-
specific responses to multiple TLRs. MyD88 then relays downstream signalling via the 
serine/threonine kinase IL-1R-associated kinases, the E3-ubiquitin ligase and 
scaffolding protein tumour necrosis factor (TNF) receptor-associated factor-6 (TRAF6) 
and the mitogen-activated protein kinases (MAPKs) [5]. This ultimately enables 
activation of pro-inflammatory transcription factors such as nuclear factor kappaB (NF-
κB) and activator protein-1 to drive inducible expression of pro-inflammatory target 
genes such as IL-1β, IL-6 and TNF-α (for reviews see [5,8,9]).  
TLR3 and TLR4 are both capable of signalling independently of MyD88, via the TIR 
domain-containing adaptor-inducing interferon (TRIF; also known as TIR-containing 
adaptor molecule 1, TICAM1) pathway [5]. TLR4 engages both MyD88 and TRIF, 
whereas TLR3 uses TRIF exclusively. TLR4 initiates the MyD88-dependent pathway at 
the plasma membrane, whilst signalling switches to TRIF-mediated responses once 
TLR4 is endocytosed [10]. Endosomal TLR4 signalling via TRIF requires the bridging 
adaptor TRIF-related adaptor molecule (TRAM; also known as TIR-containing adaptor 
molecule 2, TICAM2) [10]. TRIF signalling activates the serine/threonine kinase 
TANK binding kinase-1 (TBK-1), which phosphorylates the transcription factor 
interferon (IFN) regulating factor 3 (IRF3) [5]. IRF3 phosphorylation enables it to 
translocate to the nucleus and activate specific pro-inflammatory target genes, for 
example IFN-, which encodes a type-1 IFN [5]. 
2.2. TLR3 signalling 
Although TLR3 signalling has been extensively characterized, some new players and 
regulatory mechanisms have recently emerged (Fig. 2). TLR3 is assembled in the 
endoplasmic reticulum, from where it is recruited to endosomes by the transmembrane 
protein UNC93B1 [11]. It is the only TLR that directly recruits TRIF to its TIR domain 
to initiate signalling. This may relate to the fact that the conserved proline residue 
present in the BB-loop of most TLR TIR domains is an alanine in TLR3. Indeed, 
mutation of Ala795 in TLR3 to a proline resulted in MyD88-biased signalling [12]. As 
with TLR4 signalling, TRIF recruitment to TLR3 leads to the activation of the 
serine/threonine kinase TBK-1, which in turn phosphorylates IRF3 [13,14]. 
Phosphorylation occurs at multiple residues (e.g. Ser385, Ser386) in the C-terminal 
region of IRF3, enabling dimerization, nuclear translocation and transcription of IFN-β 
[15,16]. IFN-β signals in an autocrine fashion to activate the transcription factors signal 
transducer and activator of transcription (STAT) 1 and 2, resulting in the activation of 
type-1 IFN target genes and subsequent anti-viral responses [17]. Although IRF3 is the 
primary transcription factor driving IFN-β transcription during TLR3 signalling, other 
IRFs also function downstream of TLR3 to impart cell-specific signalling responses. 
For example, IRF6 is an epithelial cell-specific transcription factor that lies downstream 
of TLR3 signalling in keratinocytes. Specifically, it inhibits poly(IC)-inducible IFN- 
expression, while promoting poly(IC)-inducible IL-23p19 expression in primary human 
keratinocytes [18]. 
In addition to activating IRF3, TLR3 signalling via TRIF also activates NF-κB [19,20]. 
The C-terminal region of TRIF contains a receptor-interacting protein homotypic 
interaction motif (RHIM), which is essential for its interaction with the serine/threonine 
kinase receptor-interacting protein kinase (RIPK)1 [21,22]. TLR3- and TLR4-mediated 
NF-κB activation is impaired in the absence of RIPK1 [21]. RIPK1 undergoes K63-
linked polyubiquitination and interacts with TRAF6 and transforming growth factor-
beta activated kinase 1 (TAK1), resulting in NF-κB activation [23]. The TRIF-RIPK1 
axis is a central control point in cell survival/death pathways, since RIPK1 also 
associates with Fas-associated death domain (FADD), via a death domain interaction 
[22]. This subsequently leads to the assembly of a death-inducing signalling complex 
that contains caspase-8 [22]. Homodimerized caspase-8 undergoes autocatalytic 
processing and activation, leading to RIPK1 cleavage and inactivation, followed by 
apoptotic cell death [22]. However, if caspase-8 heterodimerizes with a non-
catalytically active homologue of caspase-8, FLICE-like inhibitory protein, it is 
partially activated [22]. This complex is not able to cleave RIPK1 adequately to cause 
apoptosis, and therefore mediates cell survival [22]. Furthermore, if caspase-8 activity is 
compromised, RIPK1 cleavage is completely prevented, thereby allowing it to interact 
with RIPK3 to form a necrosome, leading to necroptotic cell death [24,25]. Thus, 
RIPK1 acts as a central signalling hub in dictating whether TLR3 signalling promotes 
survival, apoptotic cell death or necroptotic cell death.  
2.3. Role of TLR3 in host defence 
The role of TLR3 in host defence was first dissected through gene knock-out studies in 
mice, revealing a role in dsRNA recognition and anti-viral responses. In macrophages 
from Tlr3
-/-
 mice, the production of the inflammatory cytokines IL-6, IL-12 and TNF- 
in response to the synthetic dsRNA analogue poly(IC), but not other TLR agonists, was 
impaired [26]. Additionally, Tlr3
-/-
 mice are highly susceptible to infection by many 
RNA viruses, including rhinovirus, influenza A virus (IAV) and respiratory syncytial 
virus [27]. Genetic association studies in humans have also linked the TLR3 pathway to 
host defence against IAV. A patient with IAV-induced encephalopathy showed a 
missense mutation (F303S) in the TLR3 gene [28]. Additionally, children with a 
particular TLR3 polymorphism (rs5743313/CT) have an increased risk of pneumonia 
caused by the pandemic IAV/H1N1 (2009) [29]. Complex roles for TLR3 in host 
protection versus immunopathology have also reported in other viral infection models, 
for example West Nile virus (WNV) [30,31]. An initial study showed that Tlr3
-/-
 mice 
were protected from WNV-induced encephalitis, because of reduced viral entry into the 
central nervous system [30]. This study also linked TLR3 to a TNF-α-mediated 
reduction in blood-brain barrier (BBB) integrity upon WNV infection. However, a 
subsequent study reported that TLR3 deficiency resulted in enhanced WNV replication 
in primary cortical neurons, and that viral replication was actually increased in the brain 
and spinal chord of Tlr3
-/-
 mice [31]. The contrasting conclusions from these studies 
[30,31] may reflect differences in viral doses and/or routes of administration used. 
These factors would likely affect the magnitude of the initial inflammatory response 
upon WNV challenge, potentially leading to differential effects on BBB integrity in the 
two models. 
Although these studies provide links between TLR3 and host responses to RNA viruses, 
most genetic studies in humans actually posit the TLR3-TRIF-IRF3 axis in responses 
against DNA viruses. The first evidence for this was the demonstration that TLR3 has a 
host protective function against the dsDNA virus, herpes simplex virus (HSV)-1 [32]. 
Patients with mutations in TLR3 and UNC93B1 are susceptible to HSV-1 encephalitis 
[32-34]. Recognition by TLR3 of intermediate dsRNA produced by HSV-1 during its 
replicative cycle likely explains this phenomenon [32]. These findings were supported 
by subsequent analysis of patients with defects in genes encoding the TLR3 signalling 
components TRIF, TBK-1 and IRF3 [35-37]. An impaired TLR3-inducible type-1 IFN 
response to HSV-1 in neurons and oligodendrocytes in the central nervous system 
(CNS) was subsequently linked with this condition [32-37]. These findings are also 
consistent with studies in mouse models of DNA virus infections. Tlr3
-/-
 mice displayed 
enhanced replication of HSV-1 in the CNS [38], and an increased susceptibility to 
HSV-2 infection in the CNS after vaginal inoculation [39]. In humans, TLR3 
polymorphisms (C1234T, rs1879026 G/T) have also been linked to increased risk to 
chronic hepatitis B virus (HBV) infection and HBV-induced hepatocellular carcinoma 
[40,41], while the C13766T TLR3 polymorphism was suggested to be protective against 
HBV infection and HBV-related liver disease [42]. A study analysing Saudi Arabian 
patients with HBV infections reported a TLR3 single nucleotide polymorphism 
(rs1879026 G/T) that was found more frequently in HBV-infected patients [40]. 
Peripheral blood mononuclear cells from HBV-infected patients were also reported to 
have increased TLR3 levels in active chronic HBV infection and related liver failure 
[43]. Collectively, these studies reveal a significant role for TLR3 signalling in 
responses to a wide range of viral pathogens.     
3. TLR3 functions in homeostasis and wound healing 
3.1. Skin 
Human skin is constantly exposed to microbes. Not surprisingly then, keratinocytes 
express TLRs, responding to PAMPs with inflammatory cytokine production. These 
cells are especially responsive to TLR3 agonists [18,44-47], and an initial study on 
human keratinocytes revealed an unexpected role for this PRR in detecting RNA 
released from damaged cells [48]. More specifically, UVB-damaged keratinocytes 
release U1 spliceosomal non-coding RNA that activates TLR3 in non-irradiated cells, 
resulting in the release of inflammatory cytokines, such as TNF-α and IL-6 [49]. These 
effects are consistent with findings from earlier studies, showing that UV-radiation 
activated NF-κB [50], triggered the pro-inflammatory MAPK p38 and c-Jun N-terminal 
kinase signalling arms [51-53], and promoted IL-6 and TNF-α release [54,55]. In light 
of subsequent studies on U1 RNA-mediated TLR3 activation, it seems likely that this 
pathway is involved in initiating these UVB-triggered inflammatory responses. 
Poly(IC)-mediated TLR3 activation also directly upregulated the expression of several 
genes encoding proteins associated with maintenance of epidermal structure, for 
example transglutaminase-1 (TGM1) [56]. In oral keratinocytes, IRF6 regulates 
Grainyhead-like 3 expression [57,58], which has been reported to directly regulate 
TGM1 transcription [59]. Thus, it is conceivable that TLR3-inducible TGM1 expression 
occurs via the IRF6-dependent pathway [18]. Finally, the importance of such responses 
in wound repair is highlighted by the observation that Tlr3
-/- 
mice exhibit chronic 
wounds and impaired re-epithelialization following acute UVB-irradiation [56].  
There is also evidence that TLR3 regulates host responses during physical injury of the 
skin. TLR3 mRNA and protein levels were upregulated in full excisional wounded skin; 
moreover, TLR3 was required for TNF-α and IL-6 production at wound edges, as well 
as optimal wound closure [48,60]. Impaired wound closure in Tlr3
-/- 
mice may be linked 
to reduced secretion of the chemokine C-X-C motif ligand (CXCL)-2, leading to 
defective recruitment of neutrophils and macrophages to the injury site [60,61]. 
Collectively, these studies demonstrate that TLR3 has a critical role in detecting cell 
damage in the skin, initiating inflammatory processes that are required for wound 
healing and directly promoting the expression of genes in keratinocytes required for 
barrier function (Fig. 3). 
Mechanistically, IRF6, an epithelial cell-specific transcription factor that is required for 
keratinocyte differentiation, may be involved in some of the above processes. IRF6 
suppressed poly(IC)-inducible IFN- mRNA, while promoting inducible IL-23p19 
mRNA expression in human keratinocytes [18]. IFN- has been shown to inhibit 
proliferation and promote terminal differentiation of keratinocytes [62,63]. Therefore, 
IRF6-mediated IFN- inhibition may enable a proliferative and reparative response in 
the skin. Intriguingly, we recently showed that poly(IC) selectively upregulates the 
expression of the IL-12 family genes IL-23p19 ( sub-unit) and Epstein-Barr virus 
induced 3 (EBI3) ( sub-unit) in keratinocytes, and that these two sub-units interact 
when co-expressed in cells [18]. This suggests that IL-23p19 and EBI3 may function as 
a novel IL-12 family cytokine.  Indeed, these two subunits were very recently reported 
to form IL-39, which was shown to promote neutrophil expansion in lupus-prone mice 
[64,65]. Therefore, IL-39 may play a role downstream of TLR3 in wound healing 
responses in the skin by promoting neutrophil-mediated responses at the site of injury. 
Interestingly, IRF6 itself has been suggested to have a role in wound healing. Patients 
with IRF6 mutation-associated cleft lip/palate disorders were more likely to have wound 
complications after corrective surgery (47% of patients), compared to patients with 
other forms of cleft lip/palate (19% of patients) [66]. This conclusion is supported by an 
in vitro study showing that IRF6 mRNA expression was upregulated in normal 
keratinocytes during scratch wounding [67]. Thus, there may be a functional connection 
between TLR3 and IRF6 in promoting wound healing responses in the skin, possibly 
involving co-expressed IL-23p19 and EBI3.  
3.2. Intestinal Tract  
IECs express functional TLRs and can initiate pro-inflammatory signalling upon 
pathogen recognition [2]. Emerging evidence also implicates epithelial-expressed TLRs 
in intestinal homeostasis and prevention of dysregulated mucosal inflammation [68]. 
Consistent with its pro-wound healing role in the skin, a tissue-protective role for TLR3 
in the intestine was observed during dextran sodium sulphate-induced colitis [69]. 
Subcutaneous poly(IC) pre-treatment protected mice from colitis, an effect not observed 
in Tlr3
-/-
 mice [69]. Levels of inducible nitric oxide synthase, cyclooxygenase-2, serum 
CXCL1/KC (derived from keratinocytes) and amyloid A were also reduced in poly(IC)-
treated mice [69]. However, other studies actually implicate TLR3 signalling in 
inducing acute injury in gut epithelia [70-72]. Intraperitoneal injection of rotavirus 
dsRNA resulted in severe injury in the small intestine as characterized by thinning of 
the intestinal wall, erosion of villi and the mucus membrane, and weight loss; Tlr3
-/-
 
mice were protected from such effects [70-72]. Poly(IC) administration also up-
regulated serum levels of several cytokines including IL-15 and IFN- [70]. IL-15 was 
shown to have a non-redundant role in driving TLR3-mediated injury, whereas IFN- 
had a protective effect [70]. Interestingly, this IL-15-dependent mechanism of intestinal 
damage has previously been reported in human patients with celiac disease, where the 
activation of intraepithelial cytotoxic T lymphocytes by IL-15 led to uncontrolled cell 
destruction and atrophy [73-76]. Poly(IC), acting via TLR3, TRIF and caspase-8, also 
induced epithelial cell apoptosis and altered the structure and function of the intestine 
[71], which may relate to host-protective functions against viral infections. Indeed, a 
subsequent study showed that epithelial-specific deletion of caspase-8 resulted in TRIF-
dependent TLR3-mediated necroptosis and a more severe inflammatory phenotype [72]. 
Finally, poly(IC) has also been reported to regulate gut permeability and induce 
oxidative stress in an epithelial cell line [77,78]. Thus, TLR3 signalling in the 
epithelium seems to contribute both to host-protective epithelial cell shedding during 
pathogen challenge, as well as cell damage and injury that can be detrimental to the 
host.  
3.3. Liver 
In healthy liver tissue, hepatic stellate cells (HSC) and resident macrophages (Kupffer 
cells) are in a quiescent state; upon injury, these cells are activated, leading to the 
release of inflammatory mediators and immune cell recruitment. HSC also undergo 
transformation into myofibroblasts, leading to increased production of extracellular 
matrix proteins; this process is a host-protective response, but causes scarring and liver 
fibrosis when dysregulated [79]. As noted above, TLR3 signalling has been implicated 
in host responses during HBV infection [40-42]. However, growing evidence suggests 
that TLR3 also contributes to the inactivation or death of activated HSC and Kupffer 
cells during liver injury, contributing to protective responses against liver damage [80] 
and fibrosis [81,82].  
Mechanistically, poly(IC) treatment attenuated lipopolysaccharide-induced liver injury 
by down-regulating TLR4 expression [83]. Poly(IC) also reduced carbon tetrachloride-
induced liver fibrosis by activating TLR3 in cytotoxic natural killer cells, resulting in 
IFN- production and apoptosis of activated HSC. This in turn inhibited the progression 
of inflammation and liver damage [81,82]. Interestingly, in an alcohol-induced liver 
injury model, TLR3 signalling activated HSC and Kupffer cells to produce the anti-
inflammatory cytokine IL-10, which subsequently antagonized TLR4 signalling and 
minimized liver injury [84]. Another study showed that poly(IC) treatment suppressed 
inflammation and fat accumulation in the liver of alcohol-injured mice [80]. These 
effects were not apparent in Tlr3
-/-
 or IL-10
-/-
 mice, suggesting that TLR3-inducible IL-
10 suppresses inflammation and steatosis [80]. Conversely, in a mouse model of 
autoimmune liver disease, TLR3 was shown to enhance CD8
+
 T-cell infiltration into the 
liver via IFN- and chemokines (e.g. CXCL9) [85]. In this case, the TLR3 pathway was 
linked to pro-inflammatory responses and the progression of liver damage [85]. This 
finding suggests that TLR3 has a complex role in liver homeostasis, and thus there is a 
need to more completely understand the mechanisms by which TLR3 exerts protective 
versus pathological effects in liver disease.  
3.4. I/R injury in the brain 
I/R injury occurs when there is insufficient blood supply in a tissue leading to oxygen 
deprivation (anoxia or hypoxia), following which blood supply is restored. In the brain, 
I/R can occur during stroke, when a blood vessel is blocked, or during cardiac arrest 
[86]. The cellular and molecular mechanisms of brain I/R injury are poorly understood, 
however, inflammatory pathways play a critical role in both injury and repair processes 
[86]. As indicated earlier (see Section 2.3), TLR3 has previously been implicated in 
mediating loss of BBB integrity and contributing to neuropathology in a mouse model 
of WNV infection [30]. Nonetheless, recent studies have reported protective effects of 
poly(IC) treatment in brain I/R injury models [87-89]. This was linked to the capacity of 
TLR3 signalling in human astrocytes to drive expression of anti-inflammatory 
cytokines, such as Ifn-, which act as neuroprotective factors [87,88]. More specifically, 
poly(IC) pre-treatment of mice or primary astrocytes increased cell viability and 
proliferation, and reduced NF-B activation and inflammatory cytokine production 
following I/R injury [87,88]. This treatment regime also triggered Irf3 phosphorylation 
and upregulated Ifn-expression, suggesting a role for this signalling arm in injury 
repair [90]. Furthermore, protection against neuronal damage was lost in Tlr3
-/-
 mice 
[90]. In vitro experiments also showed that TLR3 interacted with Fas in microglial cells, 
limiting its interaction with FADD, as well as subsequent Fas/FADD-mediated 
activation of caspase-3 and 8 and microglial cell apoptosis [90]. Together, these studies 
suggest that TLR3 signalling has the capacity to limit neurological damage during I/R 
injury.  
3.5. I/R injury in the heart 
I/R injury of the heart can be caused by angioplasty, acute myocardial infarction, 
exercise, stress-induced ischemia or coronary artery bypass surgery [91]. As opposed to 
its protective role in brain ischemic injury, TLR3 signalling has been linked to the 
pathology of myocardial I/R injury. Tlr3
-/-
 mice showed significantly attenuated 
myocardial dysfunction, myocardial apoptosis and reduced infarct size in an I/R injury 
model [92]. TLR3-mediated NF-B activation, and subsequent production of 
inflammatory mediators (e.g. TNF- and IL-1) promoted leukocyte infiltration into the 
heart leading to inflammation and organ dysfunction [92]. Tlr3 deficiency also reduced 
the levels of the I/R-inducible pro-apoptotic proteins B-cell CLL/lymphoma 2 (Bcl2)-
associated X (Bax) and Bcl2 antagonist/killer (Bak), while increasing Bcl2 expression 
[92]. Increased cardiac expression of Bcl2 is known to protect mice from I/R injury by 
preventing apoptotic cell death [93]. Subsequently, another study showed that 
myocardial I/R injury induces cardiomyocyte necrosis and release of RNA, which 
activates TLR3 signalling [94]. Moreover, RNase-treated necrotic cardiomyocytes 
failed to induce inflammatory responses, such as IL-1 production, in macrophages and 
cardiomyocytes [94]. Similarly, RNase administration in vivo reduced inflammation, 
leading to protective effects [94]. Taken together, these recent studies suggest that RNA 
released from necrotic cardiomyocytes during I/R injury promotes TLR3 signalling, 
leading to apoptotic cell death, myocardial injury and pathological sequelae. 
3.6. I/R injury in the kidney 
I/R in the kidney can induce acute injury or renal failure by triggering inflammation, 
decreasing microvascular blood flow and causing endothelial dysfunction [95]. 
Although relatively little is known of the role of TLR3 signalling during kidney 
damage, one study demonstrated that serum creatinine levels were significantly reduced 
in Tlr3
-/-
 mice following renal I/R injury [96]. This study also showed that Tlr3 
signalling is initiated early in response to acute kidney injury, and that the levels of 
angiotensin-converting enzyme and inflammatory mediators, as well as cellular 
apoptosis, necrosis and renal damage, were reduced in Tlr3
-/-
 mice [96]. Additional 
studies are now required to confirm that TLR3-dependent inflammatory responses 
contribute to kidney damage during renal I/R injury, and to uncover further insights into 
mechanisms responsible. 
4. Therapeutic implications 
The above studies clearly document non-redundant roles for TLR3 in promoting or 
impairing tissue repair in different contexts. TLR3 agonists have been widely employed 
in experimental studies [61,69,87,97], and antagonists of the TLR3 pathway, acting at 
the level of the receptor [98] or intracellular signalling molecules such as TBK-1 [99], 
have been reported. Thus, one can envisage manipulation of TLR3 signalling responses 
to promote wound repair for certain conditions. For example, the demonstration that 
treatment of wounded skin of humans and mice with poly(IC) significantly reduced 
recovery time [61] provides proof of concept for such approaches. This may be 
particularly relevant in situations where wound healing is impaired, as is commonly the 
case in patients with type II diabetes [100]. The capacity of UVB-radiation to activate 
TLR3 responses in the skin could also potentially be harnessed for the treatment of 
certain dermatological conditions [49]. Patients with psoriasis respond well to narrow 
band UVB-radiation [101], and UVA/UVB-radiation was demonstrated to have 
beneficial effects in patients with atopic dermatitis [102]. However, given that such 
approaches can have potential long-term complications, for example skin cancer, 
alternative strategies to agonise TLR3 may be more applicable.   
The literature reviewed above also identifies TLR3 as a candidate target in the context 
of I/R injury. For example, in a mouse model, poly(IC) treatment following I/R injury 
improved recovery of brain function, as assessed by neurological behaviour [89]. 
Beneficial effects were also observed in rats, using a similar approach [88]. These data 
support the potential for TLR3 agonists in brain I/R injury, such as stroke. Indeed, 
Hiltonol, a nuclease-resistant and stabilized form of poly(IC), induced IFN- production 
in astrocytes and microglia and stabilized the blood-brain-barrier, leading to reduced 
leukocyte infiltration [103]. Hiltonol has been used to boost IFN production in several 
clinical trials for many types of cancer, including brain cancer [104,105], but not yet for 
brain I/R injury. Another synthetic TLR3 ligand, Ampligen, which is composed of 
poly(IC) with a U mismatch at every 12
th
 base of the C-strand, has mainly been studied 
for activation of Th1 responses [106] and as a treatment for viral infections [107]. The 
literature reviewed here suggests that there may be merit in investigating Hiltonol, 
Ampligen and other TLR3 agonists as agents for promoting injury repair in at least 
some pathological settings, for example stroke and liver injury. 
Although TLR3 antagonists have been reported, they have not been extensively 
assessed as potential therapeutic agents. TLR3 monoclonal antibodies (CNTO4685 and 
CNTO5429) inhibited poly(IC)-induced NF-B activation in HEK293T cells expressing 
TLR3, as well as serum levels of pro-inflammatory cytokines, such as IL-6 and TNF-, 
after administration in vivo [108]. A small molecule inhibitor of TLR3 (compound 4a), 
acting at the level of ligand binding, has also been reported [98]. Proof-of-concept 
studies are now required to determine whether TLR3 antagonism is efficacious in 
animal models of intestinal inflammation, as well as I/R injury in the heart and/or 
kidney.  
5. Conclusions and outlook 
TLR3 signalling has a major role not only in immune responses during infection, but 
also in homeostasis and tissue repair following injury. The molecular mechanisms 
involved are now being unravelled, such that one can envisage the development of new 
strategies to control inflammatory responses during injury and to promote tissue repair. 
However, a major challenge is that the TLR3 pathway has both host-protective and 
pathological functions in different organs or settings, and this must be given careful 
attention in considering new therapeutic strategies involving manipulation of this 
pathway. With this caveat in mind, agonism of TLR3 or specific downstream pathways 
could be considered in the context of wound healing in the skin, liver fibrosis and brain 
I/R injury, while TLR3 antagonists may have potential for cardiac and kidney injury, as 
well as intestinal disease. A more complete understanding of epithelial cell-specific 
TLR3 signalling events may ultimately guide more targeted approaches for 
manipulating this pathway to enhance wound healing and injury repair.  
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Figure legends 
Fig. 1. TLR3 signalling in wound repair and homeostasis. 
The TLR3-TRIF signalling pathway exhibits both protective and harmful roles in injury 
repair processes in different organs.  
Fig. 2. TLR3 signalling and downstream cellular responses. 
TLR3 interacts directly with TRIF to initiate signalling. This may relate to the lack of a 
conserved proline residue, present in the BB-loop of other TLRs (Alanine 795 in 
TLR3). TRIF signalling induces IFN- expression via TBK-1 and IRF3, whilst 
epithelial cell-specific IRF6 inhibits this response. TRIF also interacts with RIPK1 to 
drive NF-κB activation and inducible expression of inflammatory genes, such as those 
encoding TNF- and IL-6. RIPK1 also acts as a signalling hub for control of TLR3-
dependent cell survival, apoptosis and necroptosis. 
Fig. 3. TLR3 signalling in the skin. 
TLR3 is activated by U1 spliceosomal non-coding RNA released during cell-damage. 
TLR3 signalling leads to the production of inflammatory mediators, such as TNF-α and 
IL-6, which enable recruitment of neutrophils and macrophages to the site of injury. 
IRF6 promotes epithelial cell-specific TLR3 signalling responses, possibly contributing 
to wound repair processes in the skin. TLR3 activation also upregulates the expression 
of genes associated with maintenance of epidermal structure, such as ATP-binding 
cassette sub-family A member 12 (ABCA12), glucocerebrosidase (GBA), acid 
sphingomyelinase (ASM) and TGM1, which are required for barrier repair. 
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